CCN2 and Hepatic fibrosis: Similarly, antisense-mediated knockdown of CTGF has been shown to suppress fibrosis or its indicators in models of type 1 and type 2 diabetic nephropathy [15], unilateral ureteral obstruction (UUO) and subtotal (5/6) nephrectomy-induced kidney fibrosis [16,17], chemically induced liver fibrosis [18], hypertrophic scarring after dermal wound repair [19], and capsular scarring and contracture surrounding breast implants [20].